108 related articles for article (PubMed ID: 27391058)
41. CDK4/6 inhibitors in breast cancer.
Dukelow T; Kishan D; Khasraw M; Murphy CG
Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
[TBL] [Abstract][Full Text] [Related]
42. [Inhibitors of cyclin-dependent kinases (CDK) - a new group of medicines in therapy of advanced breast cancer].
Sarosiek T
Pol Merkur Lekarski; 2018 Jan; 44(259):5-9. PubMed ID: 29374415
[TBL] [Abstract][Full Text] [Related]
43. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Konecny GE
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
[TBL] [Abstract][Full Text] [Related]
44. Targeting breast cancer with CDK inhibitors.
Mayer EL
Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
[TBL] [Abstract][Full Text] [Related]
45. Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
Med Lett Drugs Ther; 2017 Nov; 59(1533):185-186. PubMed ID: 29125595
[No Abstract] [Full Text] [Related]
46. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer.
Shi X; Li H; Shi A; Yao H; Ke K; Dong C; Zhu Y; Qin Y; Ding Y; He YH; Liu X; Li L; Lei L; Hai Q; Chen W; Leung KS; Wong MH; Kung HF; Lin MC
Oncol Rep; 2018 Sep; 40(3):1592-1600. PubMed ID: 29956794
[TBL] [Abstract][Full Text] [Related]
47. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.
Teh JL; Purwin TJ; Greenawalt EJ; Chervoneva I; Goldberg A; Davies MA; Aplin AE
Cancer Res; 2016 Sep; 76(18):5455-66. PubMed ID: 27488531
[TBL] [Abstract][Full Text] [Related]
48. Pfizer's CDK4/6 inhibitor approved for advanced breast cancer.
Morrison C
Nat Biotechnol; 2015 Apr; 33(4):323-4. PubMed ID: 25850040
[No Abstract] [Full Text] [Related]
49. New directions for drug-resistant breast cancer: the CDK4/6 inhibitors.
Nichols M
Future Med Chem; 2015 Aug; 7(12):1473-81. PubMed ID: 26306734
[TBL] [Abstract][Full Text] [Related]
50. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.
Pabla N; Gibson AA; Buege M; Ong SS; Li L; Hu S; Du G; Sprowl JA; Vasilyeva A; Janke LJ; Schlatter E; Chen T; Ciarimboli G; Sparreboom A
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):5231-6. PubMed ID: 25848011
[TBL] [Abstract][Full Text] [Related]
51. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
52. Cyclin-dependent kinase 4/6 inhibition in cancer therapy.
Johnson N; Shapiro GI
Cell Cycle; 2012 Nov; 11(21):3913. PubMed ID: 23032266
[No Abstract] [Full Text] [Related]
53. PROactively TACkling CDK4/6 therapy resistance.
Caksa S; Aplin AE
Nat Cancer; 2021 Apr; 2(4):372-373. PubMed ID: 35121999
[No Abstract] [Full Text] [Related]
54. Mechanism of Action and Clinical Impact of Ribociclib-Letter.
Sorscher S
Clin Cancer Res; 2017 Sep; 23(18):5657. PubMed ID: 28916618
[No Abstract] [Full Text] [Related]
55. Cancer immunotherapy: Cell cycle inhibitors boost tumour immunogenicity.
Minton K
Nat Rev Drug Discov; 2017 Sep; 16(10):679. PubMed ID: 28959946
[No Abstract] [Full Text] [Related]
56. Tumour immunology: Cell cycle inhibitors boost tumour immunogenicity.
Minton K
Nat Rev Immunol; 2017 Aug; 17(9):529. PubMed ID: 28853445
[No Abstract] [Full Text] [Related]
57. Abemaciclib: A multi-functional radiation modifier.
Naz S; Cook JA; Mitchell JB
Oncotarget; 2019 Feb; 10(12):1230-1232. PubMed ID: 30815224
[No Abstract] [Full Text] [Related]
58. CDK4/6 inhibition triggers anti-tumour immunity.
Goel S; DeCristo MJ; Watt AC; BrinJones H; Sceneay J; Li BB; Khan N; Ubellacker JM; Xie S; Metzger-Filho O; Hoog J; Ellis MJ; Ma CX; Ramm S; Krop IE; Winer EP; Roberts TM; Kim HJ; McAllister SS; Zhao JJ
Nature; 2017 Aug; 548(7668):471-475. PubMed ID: 28813415
[TBL] [Abstract][Full Text] [Related]
59. Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Gong X; Litchfield LM; Webster Y; Chio LC; Wong SS; Stewart TR; Dowless M; Dempsey J; Zeng Y; Torres R; Boehnke K; Mur C; Marugán C; Baquero C; Yu C; Bray SM; Wulur IH; Bi C; Chu S; Qian HR; Iversen PW; Merzoug FF; Ye XS; Reinhard C; De Dios A; Du J; Caldwell CW; Lallena MJ; Beckmann RP; Buchanan SG
Cancer Cell; 2017 Dec; 32(6):761-776.e6. PubMed ID: 29232554
[TBL] [Abstract][Full Text] [Related]
60. Palbociclib - from Bench to Bedside and Beyond.
Schmidt M
Breast Care (Basel); 2016 Jun; 11(3):177-81. PubMed ID: 27493617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
